Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .
Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients.
BACKGROUND R and omized trials have established statins as an agent for prevention of coronary heart disease ( CHD ) . The purpose of this study was to assess the hypothesis that st and ard-dose statin therapy has a beneficial effect in normocholesterolemic diabetic patients with CHD . METHODS AND RESULTS A prospect i ve , r and omized , open , blinded-endpoint trial was conducted from 2002 to 2004 at 55 hospitals in Japan to evaluate the effect of statins on subsequent cardiovascular events . A total number of 1,016 CHD patients ( 301 patients with type 2 diabetes mellitus [ DM ] and 715 non-DM patients ) with serum total cholesterol levels of 180 - 240 mg/dl were r and omly divided into non-statin and statin treatments . Clinical parameters were comparable between DM and non-DM groups . Serum low-density lipoprotein (LDL)-cholesterol levels were equally decreased after statin treatment in the 2 groups . Statin treatment improved prognosis in both the DM and non-DM groups ; however , the number needed to treat ( NNT ) and relative risk reduction ( RRR ) were remarkable especially in the DM group ( NNT=8 , RRR=67 % ) compared with the non-DM group ( NNT=30 , RRR=24 % ) . CONCLUSIONS St and ard-dose statin therapy provides incremental clinical benefits in DM patients with normal cholesterol levels compared with non-DM patients . The data suggest that DM patients may enjoy the pleiotropic effects of statins , independent of the LDL-cholesterol lowering effects of these agents
Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .